ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

MGNX MacroGenics Inc

4.78
0.33 (7.42%)
16 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
MacroGenics Inc NASDAQ:MGNX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.33 7.42% 4.78 4.78 4.82 4.78 4.27 4.51 3,581,134 01:00:00

MacroGenics to Present at Wedbush PacGrow Healthcare Conference

09/08/2018 11:00pm

GlobeNewswire Inc.


MacroGenics (NASDAQ:MGNX)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more MacroGenics Charts.

MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will provide a corporate overview presentation at the 2018 Wedbush PacGrow Healthcare Conference in New York on Tuesday, August 14, 2018 at 10:20 am (ET).

A webcast of the conference presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of this webcast on its website for 30 days after the conference.

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of MacroGenics, Inc.

###

Contacts:
Jim Karrels, Senior Vice President, CFO
MacroGenics, Inc.
1-301-251-5172, info@macrogenics.com

Karen Sharma, Senior Vice President
MacDougall Biomedical Communications
1-781-235-3060, ksharma@macbiocom.com

1 Year MacroGenics Chart

1 Year MacroGenics Chart

1 Month MacroGenics Chart

1 Month MacroGenics Chart

Your Recent History

Delayed Upgrade Clock